retatrutide clinical trials efficacy (RETA) is one of the most promising investigational peptides in obesity research— Today, we shared new data

The highlight of our GLP-1 treatment at NextMed Clinic is its unique action in contributing to effective weight control management

Gastrointestinal adverse events, including diarrhoea, nausea, and vomiting, were consistently the most common side effects reported across all dose groups in the phase 2 trial

A provider may prescribe a compounded medication for several reasons, allowing for a more individualized treatment plan

Crewe C, An YA, Scherer PE

Animal studies have shown that GLP-1RAs activate fat cell browning and may regulate BAT through the central nervous system

This is a class effect shared across all GLP-1 receptor agonists , not a flaw in any particular medication